TRP_1170x120_3-8-19

Paul Campanelli

HDA honors drug companies with 2017 DIANA awards

HDA honors drug companies with 2017 DIANA awards

PHOENIX — The Healthcare Distribution Alliance (HDA) this week presented its annual Distribution Industry Awards for Notable Achievements in Healthcare (DIANA) to pharmaceutical manufacturers for supply chain innovation and collaboration. Given at the HDA 2017 Business and Leadership Conference in Phoenix, the DIANA awards honor HDA member manufacturers that develop innovative new products and promotions

Endo makes changes to executive team

Endo makes changes to executive team

DUBLIN, Ireland — Endo International plc has announced executive changes in its U.S. branded drug and research-and-development units. Endo said Patrick Barry has been appointed as senior vice president of U.S. branded pharmaceuticals effective immediately and Matthew Davis as senior vice president of R&D for branded pharmaceuticals effective Jan. 3. Barry, who comes to Endo

CEO succession at Endo

CEO succession at Endo

DUBLIN, Ireland — Endo International plc has appointed Paul Campanelli, as president and chief executive officer, succeeding Rajiv De Silva, who is stepping down. Endo said Campanelli, who was president of its generic drugs and OTC business, takes the helm as president and CEO effective immediately. With the move, he will take De Silva’s spot

Endo wraps up Par Pharma acquisition

Endo wraps up Par Pharma acquisition

DUBLIN, Ireland — Endo International plc has completed its $8.05 billion acquisition of Par Pharmaceutical Holdings Inc. from leading global private investment firm TPG. Endo said Monday that with the closing of the deal, announced in May, its U.S. Generics segment that includes Par Pharmaceutical and Qualitest will be named Par Pharmaceutical, an Endo International

Endo to acquire Par for $8.05 billion

Endo to acquire Par for $8.05 billion

DUBLIN, Ireland — Endo International PLC plans to buy Par Pharmaceutical Holdings Inc. from TPG Capital North America in a deal valued at $8.05 billion. The pharmaceutical companies said Monday that the combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry’s fastest-growing and among the top five by U.S.